Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$55.9M Buy
168,877
+12,990
+8% +$4.28M 0.04% 465
2014
Q2
$49.2M Sell
155,887
-7,337
-4% -$2.21M 0.04% 458
2014
Q1
$49.9M Sell
163,224
-2,359
-1% -$749K 0.04% 404
2013
Q4
$46.3M Buy
165,583
+12,405
+8% +$3.21M 0.04% 419
2013
Q3
$36.9M Buy
153,178
+908
+0.6% +$203K 0.04% 446
2013
Q2
$32.8M Buy
+152,270
New +$32.5M 0.04% 452

Other funds holding BIIB

UBS's BIIB Position: Q3 2014 in Review

UBS increased its Biogen (BIIB) stake by 8.3% in Q3 2014, buying an estimated $4.28M and bringing the position to 168,877 shares worth $55.9M. The position accounts for 0.04% of the portfolio, ranked #465.

UBS first reported a position in BIIB in Q2 2013 and has held it in 6 quarters since. 818 funds tracked by Wall St. Rank hold BIIB as of Q3 2014.

  • UBS held 168,877 shares of Biogen worth $55.9M as of Q3 2014.
  • UBS bought 12,990 Biogen shares in Q3 2014, an estimated $4.28M.
  • Biogen made up 0.04% of UBS's portfolio in Q3 2014, its #465 holding.
  • UBS first reported a position in Biogen in Q2 2013 and has held it in 6 quarters since.
  • 818 funds tracked by Wall St. Rank held Biogen as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.